New combo aims to outsmart lung Cancer's immune evasion
NCT ID NCT05782361
First seen Apr 29, 2026 · Last updated May 12, 2026 · Updated 2 times
Summary
This early-phase study tests whether combining two drugs—tepotinib and pembrolizumab—can help treat advanced non-small cell lung cancer (NSCLC) that doesn't respond to standard immunotherapy. The trial includes 19 adults with NSCLC, some with a specific MET gene mutation. The goal is to see if tepotinib can make the cancer visible to the immune system again, potentially slowing tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DDU, Royal Marsden Hospital NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
-
Lung Unit, Royal Marsden Hospital NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, NW1 2BU, United Kingdom
Conditions
Explore the condition pages connected to this study.